ClinicalTrials.gg
Active, not recruitingNCT05430230Updated Mar 23, 2026

Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis

A Phase 4 interventional study of Naproxen 500 Mg and Placebo in Osteoarthritis, Knee, sponsored by Northwestern University. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Northwestern University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee by Northwestern University — 3 open to participants now, 5 under way, 1 of them phase 3. Osteoarthritis, Knee · Northwestern University.

Planned enrollment
10th of 12
20 · median 50
Started
2022
with 1 other
Phase 4
2 of 12
1 open now
Registered
8th of 12
by date

Among the 12 studies in Osteoarthritis, Knee by Northwestern University, this one is the 10th largest by planned enrollment, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 8th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee by Northwestern University, or all of them as a file.
02

Study summary

This is a pilot study with a 4-period double-cross-over design evaluating a treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in people with painful knee osteoarthritis.

Read the detailed description

Once screened and found eligible, participants will be entered into an initial blinded 2-week treatment period of either naproxen or placebo and then entered into an open washout period of 2 weeks. At the end of this washout, participants will then receive either naproxen or placebo for a further 2 week period followed again by a 2 week washout. This sequence will then be repeated (total of 4 treatment periods) such that all participants receive naproxen for 2 treatment periods and placebo for 2 treatment periods. The order of treatment will be randomized.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis, responder
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female >40 years of age
  2. Meet ACR criteria for knee OA
  3. Able and willing to provide
  4. Average weekly pain in the index knee based on daily pain assessments of ≥ 4/10 and \<9/10 on an 11-point NRS scale
  5. Willing to discontinue current medications taken for OA pain
  6. For women of , willing to utilize some form of or abstinence during the course of the study
  7. If taking cannabinoids, have to be on a stable dose and have this maintained for the duration of the study
  8. If receiving physical therapy or any non-pharmacologic modality(ies) for OA, these need to continue and remain stable for the duration of the study
  9. Ambulatory
  10. Have a cellphone and/or access to a computer and be able to utilize the eDiary as directed
  11. Use of medications for knee OA pain on at least 4 out of 7 days per week
  12. eDiary entries on at least 4 out 7 days per week during the observation period
  13. Sub-Group Criterion (≥12 participants): Variability of average daily pain in the index knee during the observation period of ≥ 2 points on the NRS scale on at least 4 occasions

Exclusion criteria

Exclusion criteria:

  1. History of intolerance or allergic reaction to NSAIDs
  2. Previous history of GI bleed
  3. Renal insufficiency resulting in serum creatinine > 1.5 mg/dL
  4. History of myocardial infarction in last 6 months
  5. Coexisting congestive heart failure or symptomatic atherosclerotic heart disease
  6. Use of oral anticoagulants other than aspirin ≤ 325 mg for cardiac prophylaxis
  7. Use of heparin or injectable anticoagulant
  8. Uncontrolled hypertension
  9. Any medical condition which in the judgement of the investigator would make it inappropriate for the participant to enroll in the study
  10. Use of recreational drugs
  11. Fibromyalgia
  12. Inflammatory arthropathies of any sort
  13. Chronic back pain in which pain level is greater than the OA pain
  14. Participation in another clinical trial other than one for covid or an observational and non-interventional study
  15. Use of walker or other aid for walking other than a single cane
  16. Hip pain on the ipsilateral side equal to or greater than the knee pain in the index joint
  17. Index knee cannot have had previous joint replacement surgery
  18. Arthroscopy within the past 6 months
  19. Injection of hyaluronate in the index knee in the past 6 months
  20. injection in the index knee in the past 3 months
  21. Injection of any biologic agent in the index in the past 12 months
  22. Nerve ablation for the treatment of pain in the index knee
  23. Any acute or chronic pain condition which would interfere with the evaluation of knee pain.
  24. Pregnant, nursing or planning to become pregnant during length of study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cross-over Treatment: Initial treatment with naproxen

    There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.

    Drug: Naproxen 500 Mg · Drug: Placebo

  • Experimental
    Cross-over Treatment: Initial treatment with placebo

    There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.

    Drug: Naproxen 500 Mg · Drug: Placebo

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    naproxen tablets

    Also known as: non steroidal anti inflammatory drugs (NSAID)

  • DrugPlacebo

    lactose NF

06

What researchers measure

Primary outcomes

  1. Mean of one week's daily pain ratings on Numeric Pain Scale (NRS) 0-10; higher worse

    daily pain will be collected by a web application and averaged over a 7day period; higher scores imply more pain

    Time frame: baseline to end of 14 day treatment period

Other outcomes

  1. Knee Injury and Osteoarthritis Outcome Score (KOOS) 0-100; higher better

    KOOS questionnaire

    Time frame: baseline to end of 14 day treatment period

  2. Pain Detect Questionnaire (PDQ) 0-38; higher more neuropathic

    PDQ

    Time frame: baseline to end of 14 day treatment period

  3. Positive and Negative Affect Schedule (PANAS) questionnaire 10-50; higher more positive or negative affect

    positive and negative affect

    Time frame: baseline to end of 14 day treatment period

  4. Quantitative Sensory Testing (QST) 0-100; higher is greater pain

    quantitative sensory testing parameters - temporal summation

    Time frame: baseline to end of 14 day treatment period

  5. Oswestry Disability Index (ODI) 0-50; higher is greater disability

    Oswestry Disability Index

    Time frame: baseline to end of 14 day treatment period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2027, 58 months after the start.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 58 months is above that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2022
First posted
Jun 24, 2022
StartActual
Aug 24, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Sep 1, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05430230
Responsible party
Thomas J. Schnitzer (Professor, Northwestern University) — Principal investigator
First posted
Jun 24, 2022
Start date
Aug 24, 2022
Primary completion
Jun 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Thomas J Schnitzer, MD, PhD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion